



Total Voting Rights and Block Listing Return

August 7, 2023 4:01 PM EDT

RNS Number : 55531
MaxCyte, Inc.
07 August 2023

MaxCyte, Inc.

("MaxCyte" or the "Company")

Total Voting Rights and Block Listing Return

ROCKVILLE, Md., August 07, 2023 -- MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that as of 31 July 2023, the total issued stock capital of the Company was 103,504,571 shares of common stock, \$0.01 par ("Common Stock") following further issue of new Common Stock in satisfaction of the exercise of share options. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

Block Listing Return

MaxCyte also makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:

Name of <i>applicant</i> :		MaxCyte, Inc.			
Name of scheme:		MaxCyte Long Term Incentive Plan			
Period of return:	From:	1 October 2022	To:	31 July 2023	
Balance of unallotted securities under scheme(s) from previous return:		11,529,603 ordinary shares of common stock at \$0.01 each			
<u>Plus</u> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil			
<u>Less</u> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		1,600,258 ordinary shares of common stock at \$0.01 each			
<u>Equals</u> : Balance under scheme(s) not yet issued/allotted at end of period:		9,929,345 ordinary shares of common stock at \$0.01 each			

Name of contact:	Douglas Swirsky, Chief Financial Officer
Telephone number of contact:	+1 301 944 1700

For further information, please contact:

MaxCyte Contacts:

US IR Adviser
Gilmartin Group
David Deuchler, CFA

+1 415-937-5400
ir@maxcyte.com

**Nominated Adviser and Joint Corporate
Broker**
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden

+44 (0)20 7886 2500

UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh

+44 (0)203 709 5700
[maxcyte@consilium-
comms.com](mailto:maxcyte@consilium-comms.com)

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExpERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExpERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRDZGGRKNRGFZM